Jane Street Group LLC Makes New Investment in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN)

Jane Street Group LLC purchased a new stake in shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 64,636 shares of the company’s stock, valued at approximately $78,000. Jane Street Group LLC owned 0.47% of NeuroSense Therapeutics as of its most recent SEC filing.

NeuroSense Therapeutics Stock Up 4.1%

Shares of NRSN stock opened at $1.79 on Monday. The company’s fifty day simple moving average is $1.20 and its two-hundred day simple moving average is $1.13. NeuroSense Therapeutics Ltd. has a 52 week low of $0.51 and a 52 week high of $1.80. The stock has a market cap of $24.46 million, a P/E ratio of -2.80 and a beta of 1.62.

NeuroSense Therapeutics (NASDAQ:NRSN) last posted its earnings results on Monday, April 7th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.06.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. D. Boral Capital started coverage on NeuroSense Therapeutics in a research note on Monday, May 12th. They set a “buy” rating and a $14.00 target price on the stock. D Boral Capital raised shares of NeuroSense Therapeutics to a “strong-buy” rating in a report on Monday, May 12th.

NeuroSense Therapeutics Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.